Senseonics Holdings, Inc. to Participate in the Upcoming H.C. Wainwright 26th Annual Global Investment Conference
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled to take place in New York, NY on September 10, 2024.
Key points:
- Management will present at 11:30 am ET
- One-on-one meetings will be held
- A live and recorded webcast will be available on the company's website
This conference provides Senseonics an opportunity to showcase its innovative CGM technology and engage with potential investors, potentially impacting the SENS stock.
Senseonics Holdings, Inc. (NYSE American: SENS), un'azienda di tecnologia medica specializzata in sistemi di monitoraggio continuo della glicemia (CGM) impiantabili a lungo termine per persone con diabete, ha annunciato la sua partecipazione alla 26a Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. L'evento si svolgerà a New York, NY il 10 settembre 2024.
Punti chiave:
- Il management presenterà alle 11:30 AM ET
- Incontri individuali saranno organizzati
- Una trasmissione in diretta e registrata sarà disponibile sul sito web dell'azienda
Questa conferenza offre a Senseonics l'opportunità di mostrare la sua innovativa tecnologia CGM e di interagire con investitori potenziali, influenzando potenzialmente le azioni di SENS.
Senseonics Holdings, Inc. (NYSE American: SENS), una empresa de tecnología médica especializada en sistemas de monitoreo continuo de glucosa (CGM) implantables a largo plazo para personas con diabetes, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El evento está programado para llevarse a cabo en Nueva York, NY el 10 de septiembre de 2024.
Puntos clave:
- La dirección presentará a las 11:30 AM ET
- Se llevarán a cabo reuniones uno a uno
- Se dispondrá de una transmisión en vivo y grabada en el sitio web de la empresa
Esta conferencia brinda a Senseonics la oportunidad de mostrar su tecnología CGM innovadora y de interactuar con posibles inversionistas, lo que podría influir en las acciones de SENS.
센소닉스 홀딩스 주식회사(NYSE American: SENS)는 당뇨병 환자를 위한 장기 이식형 지속 혈당 모니터링(CGM) 시스템을 전문으로 하는 의료기술 회사로, H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 뉴욕, NY에서 2024년 9월 10일에 열릴 예정입니다.
주요 사항:
- 경영진은 동부 표준시 오후 11시 30분에 발표할 예정입니다
- 개별 미팅이 진행될 예정입니다
- 회사의 웹사이트에서 실시간 및 기록된 웹캐스트가 제공될 것입니다
이번 컨퍼런스는 센소닉스가 혁신적인 CGM 기술을 소개하고 잠재 투자자들과 소통할 수 있는 기회를 제공하며, 이는 SENS 주가에 영향을 미칠 수 있습니다.
Senseonics Holdings, Inc. (NYSE American: SENS), une entreprise de technologie médicale spécialisée dans les systèmes de surveillance continue de la glycémie (CGM) implantables à long terme pour les personnes diabétiques, a annoncé sa participation à la 26e Conférence Annuelle Internationale sur les Investissements H.C. Wainwright. L'événement est prévu pour le 10 septembre 2024 à New York, NY.
Points clés :
- La direction fera une présentation à 11h30 ET
- Des réunions individuelles seront organisées
- Une diffusion en direct et enregistrée sera disponible sur le site Web de l'entreprise
Cette conférence offre à Senseonics l'occasion de présenter sa technologie CGM innovante et d'interagir avec des investisseurs potentiels, ce qui pourrait avoir un impact sur l'action SENS.
Senseonics Holdings, Inc. (NYSE American: SENS), ein Medizintechnikunternehmen, das sich auf langfristige, implantierbare Systeme zur kontinuierlichen Blutzuckermessung (CGM) für Menschen mit Diabetes spezialisiert hat, gab seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt. Die Veranstaltung findet am 10. September 2024 in New York, NY statt.
Wichtige Punkte:
- Das Management wird um 11:30 Uhr ET präsentieren
- Persönliche Treffen werden stattfinden
- Eine Live- und aufgezeichnete Webcast steht auf der Unternehmenswebsite zur Verfügung
Diese Konferenz bietet Senseonics die Gelegenheit, seine innovative CGM-Technologie zu präsentieren und mit potenziellen Investoren in Kontakt zu treten, was möglicherweise den Aktienkurs von SENS beeinflussen könnte.
- None.
- None.
GERMANTOWN, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference, being held in New York, NY.
Management is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 11:30 am ET and will hold one-on-one meetings.
Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
Investors@senseonics.com
FAQ
When is Senseonics Holdings (SENS) participating in the H.C. Wainwright Global Investment Conference?
What time is Senseonics Holdings (SENS) scheduled to present at the conference?
Where can investors access the webcast of Senseonics Holdings' (SENS) presentation?
What is the main focus of Senseonics Holdings (SENS) as a medical technology company?
